The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 10, Pages 2830-2839
Publisher
American Society of Hematology
Online
2011-07-07
DOI
10.1182/blood-2010-07-294827
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
- (2009) J. Zhou et al. BLOOD
- EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
- (2009) M.-L. Suva et al. CANCER RESEARCH
- Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression
- (2009) Z L Wu et al. CELL DEATH AND DIFFERENTIATION
- Chromatin maps, histone modifications and leukemia
- (2009) T Neff et al. LEUKEMIA
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
- (2009) T. B. Miranda et al. MOLECULAR CANCER THERAPEUTICS
- Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
- (2009) F. Sun et al. MOLECULAR CANCER THERAPEUTICS
- Epigenetics in cancer: Targeting chromatin modifications
- (2009) L. Ellis et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Polycomb gene silencing: knowns and unknowns
- (2009) Jeffrey A. Simon et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Regulation of PERK Signaling and Leukemic Cell Survival by a Novel Cytosolic Isoform of the UPR Regulator GRP78/BiP
- (2009) Min Ni et al. PLoS One
- DACT3 Is an Epigenetic Regulator of Wnt/β-Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications
- (2008) Xia Jiang et al. CANCER CELL
- In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
- (2008) Jianbiao Zhou et al. LEUKEMIA RESEARCH
- Roles of the EZH2 histone methyltransferase in cancer epigenetics
- (2008) Jeffrey A. Simon et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
- (2008) Inki Kim et al. NATURE REVIEWS DRUG DISCOVERY
- Epigenetics in Acute Myeloid Leukemia
- (2008) Christoph Plass et al. SEMINARS IN ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search